Table 1.
Clinical Characteristics of study groups.
| HTR n = 12 | HC n = 14 | p-value | |
|---|---|---|---|
| Age (years) | 13.2 [[10], [11], [12], [13], [14], [15]] | 8.7 [[8], [9], [10], [11]] | 0.001 |
| Sex (male), n (%) | 6/12 (50) | 7/14 (50) | 0.999 |
| Immunosuppressive treatment, n (%) | |||
| Tacrolimus | 11 (91.7) | na | |
| Mycophenolate | 6 (50) | na | |
| Sirolimus | 1 (8.3) | na | |
| Corticosteroids | 3 (25) | na | |
| Doses of vaccine, n (%) | <0.05 | ||
| Two doses | 3/12 (25) | 14/14 (100) | |
| Three doses | 9/12 (75) | 0 | |
| Time from last dose of vaccine to follow-up sample collection, months | <0.001 | ||
| 4.3 [1.7–4.9] | 0.6 [0.6–0.6] | ||
| SARS-CoV-2 infection, yes (%) | 5/12 (41.6) | 11/14 (78.5) | 0.054 |
| Diagnosis test, n (%) | 0.999 | ||
| SARS-CoV-2 RT-PCR | 2/5 (40) | 4/11 (36.4) | |
| SARS-CoV-2 antigenic test | 3/5 (60) | 7/11 (63.6) | |
| Symptomatic infection, yes (%) | 2/5 (40) | 7/11 (63.6) | 0.596 |
| Fever | 1/2 (20) | 6/7 (54) | |
| Cough | 1/2 (20) | 2/7 (18.1) | |
| Abdominal pain | 0 | 1/7 (9.09) | |
| Headache | 0 | 2/7 (18.1) | |
| Otalgia | 1/2 (20) | 0 | |
| Pneumonia | 0 | 0 | |
| Admission to hospital | 0 | 0 | |
| Lapse of time between infection and vaccination (%) | |||
| Prior to vaccination | 1/5 | 10/11 | 0.005 |
| Between 1st y 2nd dose | 0 | 1/11 | 0.999 |
| Between 2nd y 3rd dose | 1/5 | na | |
| After full vaccination regimen (Oct-21) | 3/5 | No data | |
| Thymus total excision, yes (%) | 12/12 (100) | 0 (0) | |
Continuous variables are expressed as medians and interquartile ranges [IQR]. Categorical variables are expressed as numbers and percentages. Two-tailed Mann-Whitney U test and X2 test were used for continuous and categorical variables respectively. Abbreviations: HTR: heart transplant recipients; HC: healthy controls; RT-PCR, reverse transcription polymerase chain reaction; na, no applicable. p-value<0.05 are in bold and 0.05≤p-value<0.1 are in italics.